

-continued

Tyr	Asn	Asn	Gly	Ile	Phe	Ile	Asp	Thr	Ala	Ala	Gln	Phe	Gly	His	Tyr
	595						600					605			
Ser	Asn	Thr	Ala	Asp	Val	Arg	Leu	Met	Asn	Gly	Gly	Gly	Thr	Ile	Lys
	610					615					620				
Ala	Asp	Phe	Asn	Thr	Asn	Gly	Phe	Gly	Ala	Met	Val	Lys	Gly	Gly	Tyr
	625				630				635						640
Thr	Trp	Lys	Asp	Gly	Asn	Gly	Leu	Phe	Ile	Gln	Pro	Tyr	Ala	Lys	Leu
				645					650					655	
Ser	Ala	Leu	Thr	Leu	Glu	Gly	Val	Asp	Tyr	Gln	Leu	Asn	Gly	Val	Asp
			660					665					670		
Val	His	Ser	Asp	Ser	Tyr	Asn	Ser	Val	Leu	Gly	Glu	Ala	Gly	Thr	Arg
		675					680					685			
Val	Gly	Tyr	Asp	Phe	Ala	Val	Gly	Asn	Ala	Thr	Val	Lys	Pro	Tyr	Leu
	690					695					700				
Asn	Leu	Ala	Ala	Leu	Asn	Glu	Phe	Ser	Asp	Gly	Asn	Lys	Val	Arg	Leu
	705				710					715					720
Gly	Asp	Glu	Ser	Val	Asn	Ala	Ser	Ile	Asp	Gly	Ala	Ala	Phe	Arg	Val
				725					730					735	
Gly	Ala	Gly	Val	Gln	Ala	Asp	Ile	Thr	Lys	Asn	Met	Gly	Ala	Tyr	Ala
			740					745					750		
Ser	Leu	Asp	Tyr	Thr	Lys	Gly	Asp	Asp	Ile	Glu	Asn	Pro	Leu	Gln	Gly
		755					760					765			
Val	Val	Gly	Ile	Asn	Val	Thr	Trp								
	770					775									

1. An isolated antibody or antigen binding fragment thereof comprising:

- a) a CDRH3 comprising the sequence set forth in SEQ ID NO: 5 or a CDRL3 comprising the sequence set forth in SEQ ID NO: 8; or
 - b) a CDRH3 comprising the sequence set forth in SEQ ID NO: 17 or a CDRL3 comprising the sequence set forth in SEQ ID NO: 20,
- optionally, wherein the isolated antibody or antigen binding fragment comprises:
- a) a CDRH1 comprising the sequence set forth in SEQ ID NO: 3;
 - a CDRH2 comprising the sequence set forth in SEQ ID NO: 4;
 - a CDRH3 comprising the sequence set forth in SEQ ID NO: 5;
 - a CDRL1 comprising the sequence set forth in SEQ ID NO: 6;
 - a CDRL2 comprising the sequence set forth in SEQ ID NO: 7; and
 - a CDRL3 comprising the sequence set forth in SEQ ID NO: 8; or
 - b) a CDRH1 comprising the sequence set forth in SEQ ID NO: 15;
 - a CDRH2 comprising the sequence set forth in SEQ ID NO: 16;
 - a CDRH3 comprising the sequence set forth in SEQ ID NO: 17;
 - a CDRL1 comprising the sequence set forth in SEQ ID NO: 18;
 - a CDRL2 comprising the sequence set forth in SEQ ID NO: 19; and

a CDRL3 comprising the sequence set forth in SEQ ID NO: 20.

2-5. (canceled)

6. An isolated antibody or antigen binding fragment thereof comprising:

- a) a VH comprising the sequence set forth in SEQ ID NO: 9 or a sequence having at least 90% identity to SEQ ID NO: 9, and a VL comprising the sequence set forth in SEQ ID NO: 10 or a sequence having at least 90% identity to SEQ ID NO: 10; or
- b) a VH comprising the sequence set forth in SEQ ID NO: 21 or a sequence having at least 90% identity to SEQ ID NO: 21, and a VL comprising the sequence set forth in SEQ ID NO: 22 or a sequence having at least 90% identity to SEQ ID NO: 22.

7-9. (canceled)

10. An isolated antibody or antigen binding fragment thereof comprising:

a CDRH1 comprising the sequence set forth as formula (I)

YTFIX₁YWX₂X₃ (I);

a CDRH2 comprising the sequence set forth as formula (II)

WIGNIX₄PX₅X₆GX₇X₈NY (II);

a CDRH3 comprising the sequence set forth as formula (III)

RX₉GX₁₀X₁₁RAMDY (III);

a CDRL1 comprising the sequence set forth as formula (IV)

QSVX₁₂X₁₃DVA (IV);